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Abstract The aim of the study was to assess the long-term
eYcacy and safety of InXiximab therapy in the treatment of
patients with Behçet’s disease refractory to standard
immunosuppressive agents. Twenty-one patients that did
not respond to corticosteroids and to at least one immuno-
suppressant (cyclosporin, methotrexate, azathioprine,
cyclophosphamide) for the presence of ocular and/or CNS
involvement were enrolled. Eighteen patients completed
the study up to 54 weeks. Stable doses of prednisone
(<10 mg/day) were permitted, immunosuppressants were
discontinued at least 4 weeks prior baseline visit. The
patients received three infusions of 5 mg/kg InXiximab (at
weeks 0, 2 and 6) and then infusions of 5 mg/kg InXiximab
every 8 weeks. At each visit data on clinical symptoms,
response to therapy and adverse events were collected. The
primary outcome of interest was to assess the clinical
eYcacy (total or partial recovery) of inXiximab. Secondary
end points were to evaluate quality of life and to monitor
the safety of the drug. Eighteen patients achieved a total
remission. Two patients achieved a partial remission and
relapsed after 3 months from discontinuation of therapy.
InXiximab was well tolerated throughout the study. A case
of non-Hodgkin lymphoma was observed within 6 months.
Minor side eVects were headache, dizziness, tachycardia
that regressed spontaneously and did not entail interruption.
Anti-nuclear antibodies were not detected during the period
of observation.
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Introduction
Behçet’s disease (BD) is a chronic inXammatory disorder
aVecting various organ systems, characterized by recurrent
oral aphthous ulcers, genital ulcers, uveitis, and skin lesions
[1, 2]. All these common manifestations are self-limiting
except for the ocular attacks. Repeated attacks of uveitis
can cause blindness [1–3]. Involvement of the gastrointesti-
nal tract, central nervous system, and large vessels is less
frequent, although it can be life threatening [1, 2, 4–6].
For most patients the treatment of BD is based on the
combination of corticosteroids and immunosuppressive
agents [7]. Despite the improvement obtained with this
strategy, relapses and failure may occur. Some patients can
also be refractory to all treatments.
The aetiology and pathogenesis of BD are unknown but
there are considerable data indicating that immunological
abnormalities are important. Several humoral and cellular
abnormalities have been described, such as the high serum
levels of IL-2, IFN-, TNF- [8–10]. These cytokines
detected in patients with active disease point to a polarized
Th1 immune response, as suggested by in vitro and in vivo
studies of experimental autoimmune uveoretinitis [11]. We
have also documented increased numbers of T lymphocytes
expressing the gammadelta receptor that overproduce TNF
in patients with active disease [12] and more recently a
role of NF-kB in protecting T cells against CD95 induced
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Case studies have indicated the eYcacy of inXiximab
treatment of patients with BD in refractory ocular [14–16],
neurological [17, 18], mucocutaneous [19], and gastroen-
terological involvement [20, 21].
This study was undertaken to assess the long-term
eYcacy and safety of anti-tumor necrosis factor  antibody
inXiximab (Remicade; Centocor Inc, Malvern, PA; Scher-
ing Plough SpA, Italy) therapy in the treatment of patients
with disease refractory to standard immunosuppressive
agents.
Patients and methods
Patients
Eligible patients were 18 years of age or older, had active
persistent BD diagnosed according to the international cri-
teria for BD [22], and a C-reactive protein concentration
>1 mg/dl. Patient inclusion criteria were: failure to respond
to corticosteroids and to at least one immunosuppressant
(cyclosporin, methotrexate, azathioprine, cyclophospha-
mide) for the presence of ocular and/or CNS involvement.
Major exclusion criteria consisted of prior use of TNF
antagonist, a history of active infections or of an episode of
major infection within 30 days prior to screening and any
uncontrolled medical condition, pregnancy or breast-feeding.
Study protocol
The study was approved by the local ethics committee. All
patients also gave their written informed consent. All
patients had a normal chest-X-ray, a negative test for tuber-
culosis. Stable doses of prednisone (<10 mg/day) were per-
mitted, immunosuppressants were discontinued at least
4 weeks prior baseline visit. The patients received three
infusions of 5 mg/kg InXiximab (at weeks 0, 2 and 6) and
then infusions of 5 mg/kg InXiximab, every 8 weeks for a
total of 1 year.
Disease and safety assessment
At each visit data on clinical symptoms, response to ther-
apy and adverse events were collected. Responses were
deWned as: complete (C) when clinical signs of activity, as
deWned by the BDCAF score [23, 24], that includes the
presence of several manifestations of the disease, by the
uveitis scoring system and by the visual activity measure-
ment [25], were absent during the 12-month observation;
partial (P) when the clinical response was incomplete;
absent (A) when clinical manifestations remained stable.
Laboratory evaluation, including erythro-sedimentation
rate (ESR), C-reactive protein (CRP), anti-nuclear antibod-
ies and routinary hepatic and renal parameters and com-
plete blood count, was also performed at baseline and
before each infusion of InXiximab.
Results
The primary outcome of interest was to assess the clinical
eYcacy (total or partial recovery) of inXiximab in patients
with active disease for whom classical immunosuppressive
therapy was insuYcient or inappropriate for all clinical
manifestation of the disease. Secondary end points were to
evaluate quality of life and to monitor the safety of the
drug. The total duration of this study was 12 months.
Patients who discontinued treatment due to lack of eYcacy
were considered to be non-responders. Data for patients
who discontinued study treatment for other reason (e.g.,
adverse events) were assessed for treatment response based
on their observed values at the time of discontinuation.
Twenty-one patients (18 males and 3 females, mean age
36 years, range 18–71) were enrolled into the study. Base-
line demographic and clinical characteristics that include
BDCAF scores and the result of therapy are shown in
Table 1. Organ involvement at presentation included cere-
bral vasculitis (n = 5), retinal vasculitis (n = 13) and poster-
ior uveitis (n = 13). Other clinical manifestations were oral
ulcers (n = 21), genital ulcers (n = 12), erythema nodosum
(n = 7). Previous disease-related treatment included predni-
sone (n = 21), cyclosporine (n = 20), azathioprine (n = 8),
cyclophosphamide (n = 2), chlorambucil (n = 1) methotrex-
ate (n = 3), colchicine (n = 8) and interferon (n = 1). Eigh-
teen patients completed the study up to 54 weeks. Eighteen
patients achieved a total remission (Tables 1, 2). Twelve of
these patients decided to continue inXiximab treatment and
remained free of symptoms. Six patients discontinued the
treatment after 1 year observation and four of them relapsed
after 3–6 months. InXiximab was able to control the other
disease manifestations. Two patients achieved a partial
remission and relapsed after 3 months from discontinuation
of therapy. The remission was achieved at a mean time of
4.8 weeks. Three patients withdrew from the study, one for
personal reason (at 37th week, responder), one during the
24th week of treatment because of a major adverse event
(non-Hodgkin lymphoma, responder) and the last for lack
of eYcacy (at 12th week). There were no recurrences after
steroid tapering. No relationship was observed between the
type of response to treatment and the duration of disease or
the type of clinical presentation. In all patients, the treat-
ments induced, also, a signiWcant and rapid reduction of
laboratory inXammatory parameters (ESR and CRP; not
shown). InXiximab was well tolerated throughout the study.123
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Discussion
The primary goals of management of patients with BD are
symptom control, early suppression of inXammation and
prevention of end-organ damage, the treatment options
being anti-inXammatory agents and immunosuppressants.
Drugs are frequently used in combination in order to maxi-
mize eYcacy while minimizing side eVects and the spec-
trum of clinical manifestations requires close
multidisciplinary co-operation for optimal care [26].
Anti-TNF alpha agents have been successfully used in a
number of inXammatory conditions other than rheumatoid
arthritis, including Crohn’s disease, ankylosing spondilytis,
psoriasis, psoriatic arthritis and necrotizing vasculitis. The
use of inXiximab in BD was Wrst described in 2001 [14] and
since then a number of case series and single reports have
been published. Initial indications for treatment were sight-
threatening uveitis and severe inXammatory gastrointestinal
disease. InXiximab has subsequently been used for severe
orogenital ulceration and for cerebral vasculitis. These ane-
doctal case studies have generally reported an immediate
and dramatic resolution of both organ-speciWc and systemic
symptoms, often in patients refractory to conventional
immunosuppression, and, to date, the number of random-
ized controlled trials in BD is increasing. DiVerences, how-
ever, exist in practical approaches to treatment and the
long-term outcome is unknown. Indeed, BD is character-
ized, generally, by an intermittent course. In these condi-
tions short course or single infusions seem to be suYcient
to suppress disease activity for long periods. On the other
hand, some patients have a chronic progressive course,
recurrent posterior uveitis and retinal and cerebral vasculi-
tis being considered of poor prognosis predictive value, and
a sustained therapy is required.
Table 1 Clinical and demographic characteristics of patients and response to therapy
Co colchicine, CsA cyclosporin A, CyP cyclophosphamide, AZA azathioprine, Chl chlorambucil, MTX methotrexate, P prednisone, PU posterior
uveitis, RV retinal vasculitis, CV cerebral vasculitis, C complete remission, P partial remission, A absent remission
a Withdrawn at the 37th week
b Withdrawn at the 12th week
c Withdrawn at the 24th week
Pts Sex Age Age at 
diagnosis
Previous treatment Refractory 
manifestations
Beginning 
of InXiximab
Results Adverse 
events
BDCAF pre- and 
after-treatment
Pre After
1 M 27 19 Co, CsA, P, IFN PU July 2003 C – 7 0
2 M 42 39 CsA, P PU, CV November 2003 Ca – 7 0
3 M 27 24 CsA, P PU November 2002 C – 6 0
4 M 71 63 CsA, P CV May 2003 C Headache 8 0
5 M 41 25 Co, CsA, P PU December 2002 C – 4 0
6 M 22 21 CsA, P PU, RV September 2003 C – 6 0
7 M 20 20 CsA, P PU, RV July 2002 C – 7 0
8 M 23 19 CsA, AZA, P RV May 2002 C – 6 0
9 M 41 31 CsA, P PU, RV February 2003 C – 4 0
10 F 53 38 CsA, AZA, Chl, P PU, CV June 2003 C – 9 0
11 M 33 32 CsA, P RV April 2004 C – 6 0
12 F 38 29 CsA, AZA, P RV March 2004 C Dizziness 7 0
13 M 41 31 CsA, AZA, P CV, PU October 2003 C – 5 0
14 M 32 25 CsA, AZA, P RV January 2003 C – 6 0
15 M 28 21 Co, CsA, AZA, P PU, RV March 2003 Ab – 4 3
16 M 39 37 Co, CsA, MTX, P PU, RV Sept 2003 P – 6 2
17 M 34 31 Co, CsA, MTX, P RV, PU February 2003 C – 10 0
18 M 18 14 Co, CsA, CyP, P RV, PU January 2001 C – 5 0
19 F 53 45 CyP, P CV January 2003 Cc Lymphoma 6 0
20 M 43 33 Co, CsA, MTX, AZA, P RV February 2003 C Tachyardia 6 0
21 M 31 16 Co, CsA, AZA, P RV March 2003 P – 5 1123
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eYcacy and safety of anti-tumor necrosis factor  antibody
inXiximab therapy in the treatment of patients with BD
refractory to standard immunosuppressive agents. The pri-
mary outcome of interest was to assess the induction of
remission, which was achieved in more than 95% of the
patients at a mean time of 4.3 weeks. Importantly, clinical
remission was achieved in several patients with persistent
disease activity despite dual or triple immunosuppressive
therapies. No response was observed in just one patient.
This patient was celiac, and it is not known whether this
was the result of a failure of inXiximab to inhibit TNF med-
iated responses or a switch to other cytokine pathways as
drivers of pathogenesis.
Anti-TNF withdrawn was followed by relapse in the two
patients that achieved a partial remission indicating that in
these patients a remission induction approach did not pro-
duce an optimal response in the medium/long term and
after stopping therapy in some responders. Indeed, there
have been several other case series providing the observa-
tion that patients frequently relapse after anti-TNF discon-
tinuation.
Secondary end point was to monitor the safety of the
drug. A patient developed a non-Hodgkin lymphoma. This
condition is extremely rare in patients with BD [27] and
probably related to anti-TNF therapy. In the other patients
inXiximab was generally well tolerated during all the period
of treatment.
A key target of biological therapy has been inhibition of
the cytokine TNF , which has been implicated as a central
proinXammatory messenger molecule in immunologically
mediated diseases and as a critical cytokine in the physio-
pathology of BD.
The observation, in this and other studies (reviewed in
Ref. [7]), of the dramatic eVect of TNF inhibition on reduc-
tion of signs and symptoms of disease and on suppression,
both in vivo and in vitro, of the number and the function of
active lymphocytes implicated in the pathogenesis of BD
[12], induces to consider anti-TNF agents are truly superior
to conventional immunosuppressive therapy. Additional
randomized placebo-controlled long-term studies of inXix-
imab in BD are warranted, however, using larger patient
groups. Furthermore, studies with planned anti-TNF dis-
continuation would have been much more interesting.
References
1. Kaklamani VG, Variopoulos G, Kaklamanis PG (1998) Behçet’s
disease. Semin Arthritis Rheum 27:197–217
2. Nussenblatt RB (1997) Uveitis in Behçet’s disease. Int Rev Immu-
nol 14:67–79
3. Nakae K, Masaki F, Hashimoto T, Inaba G, Mochizuki M, Sakane
T (1993) Recent epidemiological features of Behçet’s disease in
Japan. In: Wechsler B, Godeau P (eds) Behçet’s disease. Excerpta
Medica, Amsterdam, pp 145–151
4. Zouboulis CC, Kötter I, Djawari D et al (1997) Epidemiological
features of Adamantiades-Behçet’s disease in Germany and in
Europe. Yonsei Med J 38:411–422
5. Dilsen N, Konice M, Aral O, Öcal L, Inanc M, Gill A (1993)
Risk factors for vital organ involvement in Behçet’s disease. In:
Wechsler B, Godeau P (eds) Behçet’s disease. Excerpta Medica,
Amsterdam, pp 165–169
6. Mamo JG (1970) The rate of visual loss in Behçet’s disease. Arch
Ophthalmol 84:451–452
7. Pipitone N, Olivieri I, Cantini F, Triolo G, Salvarani C (2006) New
approaches in the treatment of Adamantiades-Behçet’s diseases.
Curr Opin Rheumatol 18:3–9
8. Sayinalp N, Ozcebe OI, Ozdenir O, Haznedaroglu IC, Dundar S,
Kirazli S (1996) Cytokines in Behçet’s disease. J Rheumatol
23:321–322
9. Frassanito MA, Dammacco R, CaVorio P, Dammacco F (1999)
Th1 polarization of the immune response in Behçet’s disease: a
putative role of interleukin-12. Arthritis Rheum 42:1967–1974
10. Triolo G, Accardo-Palumbo A, Dieli F, Ciccia F, Ferrante A,
Giardina E, Licata G (2002) Humoral and cell mediated immune
response to cow’s milk proteins in Behcet’s disease. Ann Rheum
Dis 61:459–462
11. Caspi RR (2002) Th1 and Th2 responses in pathogenesis and
regulation of experimental autoimmune uveoretinitis. Int Rev
Immunol 21:197–208
12. Triolo G, Accardo-Palumbo A, Dieli F, Ciccia F, Ferrante A,
Giardina E, Sano CD, Licata G (2003) Vgamma9/Vdelta2 T lym-
phocytes in Italian patients with Behcet’s disease: evidence for
Table 2 BCVA (best corrected visual acuity expressed as decimal
Snellen fraction) and uveitis score in BD patients before and after
inXiximab treatment
PTS Pre 
BCVA
Post 
BCVA
Pre uveitis 
score
Post uveitis 
score
1 0.2 1 4 0
2 0.2 1 4 0
3 0.4 1 4 0
4 1 1 0 0
5 0.5 1 3 0
6 0.4 1 4 0
7 0.3 0.9 5 1
8 0.6 1 3 0
9 0.3 1 4 1
10 0.2 0.9 4 0
11 0.5 1 2 0
12 0.6 1 2 0
13 0.2 0.7 4 0
14 0.5 0.9 2 0
15 0.2 0.9 4 2
16 0.05 1 4 1
17 0.05 0.9 6 0
18 0.05 0.8 5 0
19 1 1 0 0
20 0.6 1 2 0
21 0.6 0.8 3 1123
Rheumatol Int (2011) 31:33–37 37expansion, and tumour necrosis factor receptor II and interleukin-
12 receptor beta1 expression in active disease. Arthritis Res Ther
5:R262–R268
13. Todaro M, Zerilli M, Triolo G, Iovino F, Patti M et al (2005)
NFkB protects Behçet’s disease T cells against CD95 induced
apoptosis upregulating anti apoptotic proteins. Arthritis Rheum
52:2179–2191
14. SWkakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P,
Markomichelakis NN (2001) EVect of inXiximab on sight-threaten-
ing panuveitis in Behcet’s disease. Lancet 28;358(9278):295–296
15. Triolo G, Vadala M, Accardo-Palumbo A, Ferrante A, Ciccia F,
Giardina E, Citarrella P, Lodato G, Licata G (2002) Anti-tumour
necrosis factor monoclonal antibody treatment for ocular Behcet’s
disease. Ann Rheum Dis 61:560–561
16. Al-Rayes H, Al-Swallen R, Al-Balawi M et al (2008) Safety and
eYcacy of inXiximab therapy in active Behçet’s uveitis: an open-
label study. Rheumatol Int 29:53–57
17. Licata G, Pinto A, Tuttolomondo A, Banco A, Ciccia F, Ferrante
A, Triolo G (2003) Anti-tumor necrosis factor alpha monoclonal
antibody therapy for recalcitrant cerebral vasculitis in a patient
with Behçet’s syndrome. Ann Rheum Dis 62:280–281
18. Pipitone N, Olivieri I, Padula A et al (2009) InXiximab for the
treatment of neuro-Beheçet’s disease: a case series and review of
the literature. Arthritis Rheum 59:285–290
19. Goossens PH, Verburg RJ, Bredveld FC (2001) Remission of
Behçet’s syndrome with tumour necrosis factor  blocking
therapy. Ann Rheum Dis 60:637
20. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA (2001) Anti-
tumor necrosis factor monoclonal antibody therapy for gastroin-
testinal Behcet’s disease: a case report. Gastroenterology
120:995–999
21. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL
(2001) Treatment of intestinal Behcet’s syndrome with chimeric
tumour necrosis factor alpha antibody. Gut 49:725–728
22. International Study Group for Behçet’s Disease (1990) Criteria for
diagnosis of Behçet’s disease. Lancet 335:995–999
23. Bahcta BB, Brennan P, James TE, Chamberlain A, Noble BA,
Silman AJ (1999) Behçet’s disease: evaluation of a new instrument
to measure clinical activity. Rheumatology 38:728–735
24. Lawton G, Bahcta BB, Chamberlain AA, Tennant A (2004) Behçet’s
disease activity index. Rheumatology 43:73–78
25. Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization
of uveitis nomenclature (SUN) working group, Standardization of
uveitis nomenclature for reporting clinical data Results of the Wrst
international workshop. Am J Ophtalmol 140:509–516
26. Hatemi G, Silman A, Bang D, Bodaghi B et al (2008) EULAR rec-
ommendations for the management of Behçet’s disease: report of
a task force of the European Standing Committee for International
Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum
Dis
27. Katsura Y, Suzukawa K, Kojima H, Yoshida C, Shimizu S, Mukai
H, Hasegawa Y, Imagawa S, Mori N, Nagasawa T (2003) Cyto-
toxic T-cell lymphoma arising in Behcet disease. Int J Hematol
77:282–285123
